Resveratrol demonstrates multiple mechanisms against Porphyromonas gingivalis, the primary pathogen driving periodontitis progression, through antioxidant, anti-inflammatory, and antimicrobial properties that protect gingival cells and reduce bacterial virulence. This polyphenolic compound appears to interrupt the pathway by which oral pathogens enter systemic circulation and trigger inflammatory cascades linked to cardiovascular disease, neurodegeneration, diabetes, and cancer. The connection between periodontal disease and systemic health represents an underappreciated pathway for age-related conditions, particularly relevant as periodontitis affects over 47% of adults over 30. Resveratrol's dual action—directly targeting oral pathogens while modulating inflammatory responses—positions it as a potentially valuable adjunctive therapy for both oral and systemic health. However, this narrative review lacks specific dosage data, bioavailability considerations, or clinical trial results demonstrating efficacy in human populations. The mechanistic rationale is compelling, but translating these theoretical benefits into practical therapeutic protocols requires rigorous clinical validation. Given resveratrol's established safety profile and the growing recognition of the oral-systemic health connection, controlled studies examining specific formulations and dosing regimens for periodontal applications represent a logical next research priority.